New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
08:38 EDTCPXXCelator announces data, recommendation to continue CPX-351 Phase 3 study
Celator Pharmaceuticals announced that the independent Data and Safety Monitoring Board for the Company's Phase 3 clinical study of CPX-351 Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen as first-line therapy in older patients with high-risk acute myeloid leukemia has completed a planned safety review and recommended that the study should continue as planned without any modifications. The primary efficacy endpoint of the study is overall survival. The study is being conducted in the U.S. and Canada, with more than 40 leading cancer centers participating.
News For CPXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 20, 2015
07:42 EDTCPXXBioCentury to hold a conference
Subscribe for More Information
March 17, 2015
16:12 EDTCPXXCelator Pharmaceuticals sees sufficient funding into second half of 2016
Subscribe for More Information
16:11 EDTCPXXCelator Pharmaceuticals reports Q4 EPS (7c), consensus (16c)
Cash and cash equivalents as of December 31, 2014 were $32.4M, compared to $23.6M as of December 31, 2013. The following are expected milestones for the company: CPX-351 Phase 3 study: 2Q15 Induction response rate; 1Q16 Overall survival data. Technology platform: 3Q15 information packages for novel combinations.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use